


**Contact:**

Michael Bolick

Michael.Bolick@SelahTechnologies.com

Mobile: 864-630-4034



Different excitation wavelengths

Company:

Selah Technologies, LLC
657 South Mechanic Street
Pendleton, SC 29670
(864) 646-5888 main
(864) 646-5347 fax
www.selahtechnologies.com

Industries:

Biotechnology, nanotechnology, and advanced materials

Executive Management:

Michael Bolick, Founder & CEO
Ken Morgan, COO
Andrew Metters, CTO
Warren Weeks, VP Prod. Dev.

Employees:

Nine (9) fulltime employees

Products:

Selah DotsTM
(US Publication No. 20080113448)

Selah TubesTM
(US Patent No. 7,374,685)

Market Applications:

Fluorescent imaging agents for In Vitro Diagnostics and Clinical Oncology; Flexible electronics

Funding:

Series A \$1.6MM (closed May 2008)
Series B (anticipated in Q2'09)

Selah Technologies, LLC is a privately held advanced materials innovator and manufacturer focused on the development of nanotechnology enabled products primarily for the biomedical industry with supplementary applications in consumer electronics. These innovative products are based on two proprietary technologies, branded Selah DotsTM and Selah TubesTM. The Company has established relationships with market leading companies to accelerate adoption of its innovative products within these highly profitable markets. Today, Selah Technologies is "*materials focused and application driven*" with a mission to consistently deliver high quality nanomaterials and application-specific nano-enabled products to the global marketplace.

Applications

Selah DotsTM are designed to be used as bio-sensing and bio-imaging contrast agents, replacing fluorescent dyes, microbeads and heavy metal based quantum dots. Selah DotsTM have a host of other additional applications including usage in security inks and as authenticity and anti-counterfeiting taggants. Selah TubesTM have direct applications in flexible electronics as a replacement for indium tin oxide.

Total Available Markets

Selah DotsTM: The global market for *in vitro* diagnostics (IVDs) was worth \$42 billion in 2007 and is expected to grow 6% annually to \$56 billion by 2012. Driving growth will be the introduction of innovative technologies for molecular diagnostics and point-of-care testing. Changing population demographics will place more emphasis on diagnostics for cancer, cardiovascular diseases and metabolic diseases. In these areas innovative technologies, like Selah DotsTM, will improve detection and monitoring possibilities. Selah Technologies is initially targeting three sub-segments of the IVD market: molecular diagnostics, immunoassays, and histopathology/cytopathology. Molecular diagnostics identify disease by analyzing genetic material (e.g. DNA or RNA). Immunoassays test the concentration of a substance within biological fluid. Histopathology/cytopathology tests are used to diagnose disease at the tissue and cellular level. Selah DotsTM would replace fluorescent imaging agents within these segments.

Selah TubesTM: Within flat panel displays (FPDs) such as a LCD television, information is transmitted through an electrically conductive, brittle, transparent glass made with indium tin oxide (ITO). The global market for FPDs is \$100 billion dollars per year and growing rapidly. The ITO replacement market in FPDs is currently worth approximately \$1 billion and has been growing at an annual rate of 10%. Selah TubesTM allow control over the electrical conductivity of SWNTs enabling the replacement of expensive and supply chain challenged ITO.



Contact:
Michael Bolick
Michael.Bolick@SelahTechnologies.com
Mobile: 864-630-4034

Technology and IP

Selah Technologies obtained a worldwide exclusive license from Clemson University in 2006 to develop and commercialize two nanotechnologies. Selah Dots™ are patent-pending (US Publication No. 20080113448), brightly luminescent nanoparticles built around a core of ordinary inert carbon that can be covalently passivated with biocompatible functional groups. Selah's highly innovative and scalable manufacturing process is compatible with standard process equipment. The robustness of our process produces highly consistent and photostable fluorescent nanoparticles which are readily soluble in water and a variety of solvents. The use of carbon solves many issues associated with previous quantum dot nanoparticle approaches. It provides a cost-effective starting material and simple process route suitable for large scale production, and avoids toxicity concerns. Selah Dots™ can be produced at a level that is cost-competitive with existing dyes and substantially less expensive than high-performance dyes and cadmium-based quantum dots.

Selah Tubes™, enriched carbon single walled nanotubes (SWNTs), offering greater strength, light weight, enormous electrical conductivity, mechanical flexibility and are an excellent option to replace ITO thin films or as electrically and/or thermally conductive media. Selah's scalable process is poised to be the first to provide commercial quantities of metallic enriched or semiconducting enriched SWNTs. The production of Selah Tubes™ is protected under US Patent No. 7,374,685.

Competition

Selah Dots™: The competition to replace fluorescing dyes with Selah Dots™ requires improved performance characteristics (photostability, brightness) at cost-competitive pricing. The primary competition for fluorescent dyes and heavy-metal based quantum dots comes from Invitrogen Corporation. Evident Technologies, and to a lesser extent, Sigma Aldrich also offer quantum dots solutions.

Selah Tubes™: There are various approaches to enrich SWNTs reported in academic papers that range from destroying one of the fractions to preferentially enrich the other fraction to ultracentrifugation. NanoIntegris offers very small quantities of enriched SWNTs; however, their high-G ultracentrifugation process is not likely to be commercially scalable. SouthWest Nanotechnologies offers an enriched semiconducting-fraction of SWNTs in gram quantities but does not offer a metallic-fraction product.

The Team

Michael Bolick, Founder and CEO, founded Selah in May 2006. In December 2006, Michael graduated from the inaugural class of the Kauffman Foundation's FastTrac® TechVenture program at the Advanced Technology Development Center in Atlanta Georgia. Michael has more than 17 years experience in starting and growing advanced materials manufacturing companies. The ten years prior to Selah were focused on serving the pharmaceutical industry as an executive with a Greenville based contract research and manufacturing company. In addition to his leadership at Selah, Michael serves on the National Cancer Institute's SBIR Bridge Award Review Panel, on the External Advisory Board of the University of South Carolina's NanoCenter, as a board member for the Rutland Institute of Ethics, and on the Greenville, SC Chamber's Board of Governors. Michael holds a BS Degree in Chemical Engineering from North Carolina State University.

Ken Morgan, COO, is a 22 year veteran of the pharmaceutical, chemical and biotechnology industries specializing in the areas of technology development and transfer and manufacturing design, start up and validation. Ken was involved with multiple startup companies developing strategic plans for commercialization of novel new technologies at the Gorlin Companies. This included evaluating investment opportunities in terms of business and technological viability. Prior to working with the Gorlin Companies, Ken was President of IRIX Manufacturing, Inc. Before that, he was the site manager for Lonza Group, Ltd. at its active pharmaceutical ingredients manufacturing facility. Ken holds a MS Degree in Chemical Engineering from the University of Alabama.



Contact:
Michael Bolick
Michael.Bolick@SelahTechnologies.com
Mobile: 864-630-4034

The Team (continued)

Dr. Andrew Metters, CTO, has more than 10 years experience as a research scientist developing advanced polymer chemistries in both industrial and academic environments. Following his employment with the 3M Company as a Process Development Engineer and receipt of his Chemical Engineering PhD from the Chemical and Biological Engineering Department at the University of Colorado, Andrew trained as an International Postdoctoral Fellow in the laboratory of Jeffrey Hubbell at the Swiss Federal Institute for Technology (ETH) in Zurich, Switzerland.

Warren Weeks, Vice President of Product Development, has more than 10 years of executive management experience starting new companies, developing new products and advancing new technologies. His experience offers a unique blend of business acumen and technical proficiency. Warren has worked at Cree, Inc., he co-founded Nitronex Corporation and he served on the executive startup team at Intrinsic Semiconductor Corporation. His functional expertise in business development, strategy and business operations is coupled with his entrepreneurship in advanced materials, ceramics and microelectronics. Warren holds a BS Degree in Ceramic Engineering from Clemson University and a MS Degree in Materials Sciences & Engineering from North Carolina State University.

Dr. Hui Hu, Senior Scientist, has 13 years of research experience in chemistry, materials science and nanotechnology with 33 journal publications. Her most recent position was in nanotechnology research at the Center of Nanophase Material Science at the Oak Ridge National Laboratory. She has six years of corporate R&D experience working at Carbon Solutions, Inc. and SouthWest Nanotechnologies, Inc.

Dr. Bin Zhao, Senior Scientist, has 12 years of multidisciplinary research in organic chemistry, polymer science and nanotechnology. He has a record of 32 journal publications and 3 patents and most recently held a research position at the Center of Nanophase Material Science at the Oak Ridge National Laboratory. He worked three years in development at nanotubes manufacturer Carbon Solutions, Inc.